Billionaire Druckenmiller and Jim Cramer Like These Stocks

7. Natera, Inc. (NASDAQ:NTRA)

Number of Hedge Fund Holders: 74

Natera, Inc. (NASDAQ:NTRA) is among the stocks that Billionaire Druckenmiller and Jim Cramer like.

William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rating on the company’s stock on April 14, 2026. The firm recommends the stock as a core, long-term growth holding. William Blair highlights Natera, Inc. (NASDAQ:NTRA)’s leadership in major diagnostic markets and its diversified, expanding portfolio, positioning the company as a top investment choice in the medical technology sector.

Separately, on April 13, 2026, Natera, Inc. (NASDAQ:NTRA) highlighted positive interim results from Allogene Therapeutics’ (ALLO) registrational ALPHA3 trial, which uses the company’s CLARITY MRD assay. The study evaluates cema-cel CAR T therapy in patients with large B-cell lymphoma who remain positive for molecular residual disease (MRD) after initial treatment. Analysis showed 58.3% of MRD-positive patients achieved clearance with cema-cel. Median plasma ctDNA levels went down 97.7% in the treatment arm, compared to a 26.6% increase in the observation group. These findings offer early evidence of drug performance and reflect Natera, Inc. (NASDAQ:NTRA)’s phased variant technology in identifying high-risk patients.

Notably, the fourth quarter of 2025 established the stock as the largest holding at 12.8% of Druckenmiller’s portfolio. While acknowledging its growth in diagnostic testing, Jim Cramer takes a cautious view of the company.

Founded in 2003, Natera, Inc. (NASDAQ:NTRA) is a leader in cell-free DNA (cfDNA) and genetic testing. The Texas-based company specializes in high-sensitivity molecular diagnostics across three primary domains: women’s health (NIPT), oncology (MRD), and organ health (transplant rejection).